PATENT CLAIM ANALYSIS

Application Number: 15979041
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "402000"]

Abstract:
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

Claim (Index 36):
The method of  claim 35  wherein the drug therapy comprises the administration of bisantrene and wherein the drug combination is a drug combination selected from the group consisting of:\n (a) use with fraudulent nucleosides; \n (b) use with fraudulent nucleotides; \n (c) use with thymidylate synthetase inhibitors; \n (d) use with signal transduction inhibitors; \n (e) use with cisplatin or platinum analogs; \n (f) use with alkylating agents; \n (g) use with anti-tubulin agents; \n (h) use with antimetabolites; \n (i) use with berberine; \n (j) use with apigenin; \n (k) use with colchicine or an analog thereof; \n (l) use with genistein; \n (m) use with etoposide; \n (n) use with cytarabine; \n (o) use with camptothecins; \n (p) use with vinca alkaloids; \n (q) use with topoisomerase inhibitors; \n (r) use with 5-fluorouracil; \n (s) use with curcumin; \n (t) use with rosmarinic acid; \n (u) use with mitoguazone; \n (v) use with meisoindigo; \n (w) use with imatinib; \n (x) use with dasatinib; \n (y) use with nilotinib; \n (z) use with epigenetic modulators; \n (aa) use with transcription factor inhibitors; \n (ab) use with taxol; \n (ac) use with homoharringtonine; \n (ad) use with pyridoxal; \n (ae) use with spirogermanium; \n (af) use with caffeine; \n (ag) use with nicotinamide; \n (ah) use with methylglyoxalbisguanylhydrazone; \n (ai) use with poly-ADP ribose polymerase (PARP) inhibitors; \n (aj) use with EGFR inhibitors; \n (ak) use with Bruton's tyrosine kinase (BTK) inhibitors; \n (al) use with bis-[thio-hydrazide] amides; \n (am) use with succinimide or maleimide derivatives as inhibitors of topoisomerase II; \n (an) use with histone deacetylase (HDAC) inhibitors; and \n (ao) use with immunostimulants; \n (ap) use with telomerase inhibitors; \n (aq) use with agents that inhibit the expression or activity of Her2; \n (ar) use with agents that inhibit the expression or activity of estrogen receptors; \n (as) use with agents that inhibit the expression or activity of antigens associated with specific tumor targets; \n (at) use with G-quadruplex ligands; \n (au) use with polycyclic lysophosphatidic receptor antagonists; \n (av) use with anti-CTGF agents; \n (aw) use with myeloid differentiation inducing agents; \n (ax) use with covalent diabodies binding to a tumor-associated antigen; \n (ay) use with bispecific antibodies that have a cell-penetrating determinant and an intracellular target-binding determinant; \n (az) use with multidomain molecules that comprise a cell binding ligand that binds to cells in the tumor stroma such as endothelial cells, fibroblasts, or immune cells and an oligonucleotide that inhibits the nonsense-mediated decay pathway; \n (ba) use with tumor-specific antibodies binding to a portion of the CD44 protein or a binding protein derived from the light-chain or heavy-chain complementary-determining regions of such antibodies; \n (bb) use with inhibitors of CXCR4; \n (bc) use with pyruvate dehydrogenase kinase (PDK1) inhibitors; \n (bd) use with epherin receptor targeting agents; \n (be) use with binding proteins for Axl; \n (bf) use with Wnt pathway inhibitors together with MAPK pathway inhibitors; \n (bg) use with TEC family kinase inhibitors; \n (bh) use with substituted macrocyclic compounds with proteasome activity; \n (bi) use with peptide-based PACE4 inhibitors; \n (bj) use with azaindole derivatives as JAK3 inhibitors; \n (bk) use with inhibitors of Myc; \n (bl) use with inhibitors of furin and other pro-protein convertases; \n (bm) use with GPBP-1 inhibitors, optionally together with a p21 inhibitor; \n (bn) use with PGE 2  inhibitors; and \n (bo) use with activatable antibodies targeting tumor-specific markers.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 93.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14907728', '14907729', '13817096', '14753911', '14245738']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7895074990995117
- 35 USC 102 Novelty (BERT): 0.5337529643054688
- Combined Prediction Score: 0.7639320456201074
- Mean Citation Score: 267.787678
- Max Citation Score: 348.62634
- Similarity Product: 250.26668571904423

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test